DT-diaphorase: Possible roles in cancer chemotherapy and carcinogenesis

Oncology Research

Volumn 9, Issue 6-7, 1997, Pages 339-349

  Rauth, A M ^a   Goldberg, Z ^a   Misra, V ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Bioreductive activation; Dt diaphorase; Polymorphism

Indexed keywords

REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

AMINO ACID SEQUENCE; ANIMAL; ENZYMOLOGY; HUMAN; MOLECULAR GENETICS; MOUSE; NEOPLASM; PHYSIOLOGY; RAT; REVIEW; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASMS; RATS; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 0031304246     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Ernster, L.; Navazio, F. Soluble diaphorase in animal tissues. Acta Chem. Scand. 12:595-602; 1958.
2. Ernster, L. DT-diaphorase: A historical review. Chemica Scripta27A:l-13; 1987.
3. Ernster, L.; Ljunggren, M.; Danielson, L. Purification and some properties of a highly dicoumarol-sensitive liver diaphorase. Biochem. Biophys. Res. Commun. 2:88-92; 1960.
4. Gustafson, D. L.; Pritsos, C. A. Enhancement of xanthine dehydrogenase mediated mitomycin C metabolism by dicoumarol. Cancer Res. 52:6936-6939; 1992.
5. Wallin, R.; Rannels, S. R.; Martin, L. F. DT-diaphorase and vitamin K-dependent carboxylase in liver and lung microsomes and in macrophages and type II epithelial cells isolated from rat lung. Chemica Scripta 27A:193-202; 1987.
6. Beyer, R.L.; Segura-Aguilar, J.; DiBernardo, S.; Cavazzani, M.; Fato, R.; Fiorentini, D.; Galli, M. C.; Getti, M.; Landi, L.; Lenaz, G. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. Proc. Natl. Acad. Sci. USA 93:2528-2532; 1996.
7. Talalay, P. Mechanisms of induction of enzymes that protect against chemical carcinogenesis. Adv. Enzyme Regul. 28:149-159; 1989.
8. Iyanagi, T.; Yamazaki, I. One-electron-electron reactions in biochemical systems. V. Differences in the mechanism of quinone reduction by the NADP dehydrogenase and the NAD(P)H dehydrogenase (DT-diaphorase). Biochem. Biophys. Acta 216:282-294; 1970.
9. Ross, D.; Beau, H.; Traver, R. D.; Siegel, D.; Phillips, R. M.; Gibson, N. W. Bioactivation of quinones by DT-diaphorase: Molecular, biochemical and chemical studies. Oncol. Res. 6: 493-500; 1994.
10. Cadenas, E. Antioxidant and prooxidant functions of DTdiaphorase in quinone metabolism. Biochem. Pharamacol. 49:127-140; 1995,
11. Buffington, G. D.; Ollingér, K.; Branmark, A.; Cadenas, E. DT-diaphorase-catalyzed reduction of 1,3-naphthoquinone derivatives and glutathionyl-quinone conjugates. Effect of substituents on autooxidation rates. Biochem. J. 257:561-571; 1989.
12. Lin, A. J.; Cosby, L. A.; Sartorelli, A. C. Potential bioreductive alkylating agents. In: Sartorelli, A. C., eds. Cancer chemo. Washington: American Chemical Society; 1976: 71-86.
13. Sartorelli, A. C. Therapeutic attack of hypoxic cells of solid tumours: Presidential address. Cancer Res. 48:775-778; 1988.
14. Rockwell, S. Use of hypoxia-directed drugs in the therapy of solid tumours. Semin. Oncol. 19(4)(Suppl.) 1:29-40; 1992.
15. Workman, P. Enzyme-directed bioreductive drug development revisited: A commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncol. Res.'6:461-475; 1994.
16. Sartorelli, A. C.; Hadnick, W. F.; Beicourt, M. F.; Tomasz, M.; Haffty, B.; Fischer, J. J.; Rockwell, S. Mitomycin C: A prototype bioreductive agent. Oncol. Res. 6:501-508; 1994.
17. Rauth, A. M.; Marshall, R. S.; Kuehl, B. L. Cellular approaches to bioreductive drug mechanisms. Cancer Metastasis Rev. 12:153-164; 1993. -
18. Brown, J. M. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br. J. Radiol. 52(620):650-656; 1979.
19. Haffty, B. G.; Son, Y. H.; Papac, R.; Sasaki, C. T.; Weissberg, J. B.; Fischer, D.; Rockwell, S.; Sartorelli, A. C.; Fischer, J. J. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: Results of the Yale mitomycin randomized trials. J. Clin. Oncol. 15:268-276; 1997.
20. Flam, M.; John, M.:; Pajak, T. F.; Petrelli, N.; Myerson, R.; Doggett, S.; Quincy, J.; Rotman, M.; Kerman, H.; Coia, L.; Murray, K. Role of mitomycin in combination with fluorouracil and radiotherapy and of salvage chemo radiation in the definitive non-surgical treatment of epidermoid carcinoma of the anal canal: Results of a phase HI randomized intergroup study. J. Clin. Oncol. 14:2327-2539; 1996.
21. Fitzsimmons, S. A.; Workman, P.r Grever, M.; Paull, K.; Carnalier, R.; Lewis, A. D. Reductase enzyme expression across the National Cancer Institute tumour cell line panel: Correlation with sensitivity to mitomycin C and EO9. J. Natl. Cancer Inst. 88:259-269; 1996.
22. Beicourt, M. F.; Hodnick, W. F.; Rockwell, S.; Sartorelli, A. C. Bioactivation of mitomycin antibiotics by aerobic and hypoxic Chinese hamster ovary cells overexpressing DTdiaphorase. Biochem. Pharmacol. 51:1669-1678; 1996.
23. Gustafson, D. L.; Beall, H. D.; Bolton, E. M.; Ross, D.; Waldren, C. A. Expression of human NAD(P)H:quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: Effect on the toxicity of antitumour quinones. Am. Soc. Pharmacol. Exp. Ther. 50:728-735; 1996.
24. Kuehl, B. L.; Bûchwald, M.; Rauth, A. M. Characterization of a set of Chinese hamster ovary variant cell lines demonstrating differing sensitivity to mitomycin C. Oncol. Res. 5: "213-221; 1993.
25. O'Dwyer, P. J.; Perez, R. P.; Yao, K-S.; Godwin, A. K.; Hamilton, T: C. Increased DT-diaphorase expression and cross-resistant human ovarian cancer cell lines. Biochem. Pharmacol. 52:21-27; 1996.:
26. Jaiswal, A.'; McBridè, O. W.; Adesnik, M.; Neben. D. W. Human dioxin-inducible cytosolic NAD(P)H:menadione oxidoreductase cDNA sequence and localization of gene to chromosome 16: J. Biol. Chem. 263:13572-13578; 1988.
27. Chen, S.; Clarke, P. E.; Martino, P. A.; Deng, P. S-K.; Yeh, C-H.; Lee, T. D.; Prochaska, H. J.; Talalay, P. Mouse liver NAD(P)H:quinone acceptor oxidoreductase. ' Protein sequence analysis by tandem mass spectrometry.'cDNA cloning and expression in E. coli. Protein Sci. 3:1296-1304; 1994.
28. Bayney, R. M.; Rodkey, J. A.; Bennett, C. D.; Lu, A. Y. H.; Pickett, C. B. Rat liver NAD(P)H:quinone reductase nucleotide sequence analysis of a quinone r.eductase cDNA clo,ne and prediction of the amino acid sequence of the corresponding protein. J. Biol. Chem. 262:572-575; 1987.
29. Chen, S.; Knox, R.; Lewis, A. D.; Friedlos, F.; Workman, P.; Dengr P. S. K.; Fung, M.; Ebenstein, D.; Wu, K.; Tsai, F. M. Catalytic properties of NAD(P)H:quinone acceptor oxidoréductase: Study involving mouse, rat, human and mouse-rat chimeric enzymes. Mol. Pharmacol. 47:934' 939;1995.
30. Bayney, R. M-.; Morton, M. R.; Favreau, L. V.; Pickett, C. B. Rat liver NAD(P)H:quinone reductase. Regulation of quinone reductase gene expression by planar aromatic compounds and determination of the exon structure of the quinone reduc' tase structural gene. J. Biol. Chem. 264(36):21793-21797; 1989.
31. Jaiswal, A. K. Human NAD(P)H:quinone oxidoréductase (NQO,) gene structure and induction by dioxin. Biochemistry 30:10647-10653; 1991.
32. Jaiswal, A. K.; Burnett, P.; Adesiuk, M.; McBride, O. W. Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoréductase gene family. Extensive polymorphism at the NQO gene locus on chromosome 6. Biochemistry 29:1899-1906; 1990.
33. Joseph, P.; Xie, T.; Xu, Y.; Jaiswal, A. K. NAD(P)H:quinone oxidoreductasel (DT-diaphorase): Expression regulation, and role in cancer. Oncol. Res. 6:525-532; 1994.
34. Vasiliou, V.; Shertzer, H. G.; Liu, R. M.; Sainsbury, M.; " Nebert, D. W. Response of [Ah] battery genes to compounds that protect against menadione toxicity. Biochem. Pharmacol. 50:1885-1891; 1995.
35. Yao, K. S.; O'Dwyer, P. J. Involvement of NF-xB in the induction of NAD(P)H:quinone oxidoréductase (DTdiaphorase) by hypoxia, oltipraz and mitomycin C. Biochem. Pharmacol. 49:275-282; 1995.
36. Li, R.; Bianchet, M. A.; Talalay, P.; Amzel, L. M. The threedimensional structure of NAD(P)H:quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: Mechanism of the two-electron reduction. Proc. Natl. Acad. Sci. USA 92:8846-8850; 1995.
37. Ma, Q.; Cui, K.; Wang, R. W.; Lu, A. Y. H.; Yang, C. 'S. Site-directed mutagenesis of rat liver NAD(P)H:quinone oxidoréductase: Rôles of lysine 76 and cysteine 179. Arch. Biochem. Biophys. 294(2):434-439; 1992.,
38. Ma, Q.; Cui, K.; Xiao, F.; Lu, A. Y. H.; Yarig, C. S. Identification of a glycine-rich sequence as an NAD(P)H-binding site and tyrosine 128 as a dicumarol-binding site in rat liver NAD(P)H:quinone oxidoréductase by site-directed mutageneiis. J. Biol. Chem. 267(31):22298-222-304; 1992.
39. Rauth, A. M.; Mohindra, J. K,; Tannock, I. F. Activity of mitomycin C for aerobic and hypoxic cells in vitro and in vivo. Cancer Res. 43:4154-4158; 1983.
40. Marshall, R. S.; Rauth, A. M. Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a milomycin C analogue, in Chinese hamster ovary cells. Cancer Res. 48:5655-5659; 1988.
41. Paterson, M. C.; Middlestadt, M. V.; Weinfeld, M.; Mirzayans, R.; Centner, N. E. Human cancer-prone disorders, abnormal carcinogen response, and defective DNA metabolism. In: Burns, F. J.; Upton,. A. C.; Silini, G., eds. Radiation carcinogenesis and DNA alterations. NATO ASI Series A Vol. 124:471-498; 1986.
42. Marshall, R. S.; Paterson, M. C.; Rauth, A. M. Deficient activation by a human cell strain leads to mitomycin C resistance under aerobic but not hypoxic conditions. Br. J. Cancer 59:341-346; 1989.
43. Marshall, R. S.; Paterson, M. C.; Rauth, A. M. Studies on the mechanism of resistance to mitomycin C and porfiromycin in a human cell strain derived from a cancer-prone individual. Biochem. Pharmacol. 41:1351-1360; 1991.
44. Marshall, R. S.; Paterson, M. C.; Rauth, A. M. DT-diaphorase activity and mitomycin C sensitivity in non-
45. transformed cell strains derived from members of a cancerprone family. Carcinogenesis 12:1175-1180; 1991.
46. Rauth, A. M.; Marshall, R. Mechanisms of activation of mitomycin C and AZQ in aerobic and hypoxic mammalian cells. In: Adams, G. E., ed. Selective activation of drugs by redox processes. New York: Plenum Press; 1990:113-123.
47. Traver, R. D.; Horikoshi, T.; Danenberg, K. D.; Stadibauer, T. H. W.; Danenberg, P. V.; Ross, D.; Gibson, N. W. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: Characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res. 52:797-802; 1992.
48. Wu., K.; Den, P. S-K.; Chen, S. Catalytic properties of a naturally occurring mutant of human NAD(P)H:quinone acceptor oxidoreductase (DT-diaphorase), Pro 187 to Ser. In: Yagi, K., ed. Pathophysiology of lipid peroxides and related free radicals. Tokyo: Japan Scientific Societies Press; in press.
49. Kuehl, B. L.; Paterson, J. W. E.; Peacock, J. W.; Paterson, M. C.; Rauth, A. M. Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br. J. Cancer 72:555-561; 1995.
50. Ross, D.; Traver, R. D.; Siegel, D.; Kuehl, B. L.; Misra, V.; Rauth, A. M. A polymorphism in NAD(P)H:quinone oxidoreductase (NQO1): Relationship of a homozygous mutation at position 609 of the NQO1 cDNA to NQOI activity. Br. J. Cancer 74:995-996; 1996.
51. Eickelmann, P.; Schulz, W. A.; Rohde, B.; Schmitz-Drager, B.; Sies, H. Loss of heterozygosity at the NAD(P)H:quinone oxidoreductase locus associated with increaed resistance against mitomycin C in a human bladder carcinoma cell line. Biol. Chem. HoppeSeyler 375:439-445; 1994.
52. Rosvold, E. A.; McGlynn, K. A.; Lustbader, E. D.; Buetow, R. H. Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics 5:199-206; 1995.
53. Kolesar, J. M.; Kühn, J. G.; Burris, H. A. Comment on: Detection of a point mutation in NQOI (DT-diaphorase) in a patient with colon cancer. J. Natl. Cancer Inst. 87:1802-1803; 1995.
54. Rosvold, E. A.; McGlynn, K. A.; Lustbader, E. D.; Buetow, K. H. Comment on: detection of a point mutation in NQOI (DT-diaphorase) in a patient with colon cancer. J. Natl. Cancer Inst. 87:1802-1803; 1995.
55. Traver, R. D.; Siegel, D.; Beall, H. D.; Phillips, R. M.; Gibson, N. W.; Franklin, W. A.; ROSS, D. Characterization of a polymorphism in NAD(P)H:quinone oxidoreductase (DTdiaphorase). Br. J. Cancer 75:69-75; 1997.
56. Edwards, Y. H.; Potter, J.; Hopkinson, D. A. Human FADdependent NAD(P)H diaphorase. Biochem. J. 187:429-436; 1980.
57. Shaw, P. M.; Reiss, A.; Adesnik, M.; Neben, D. W.; Schenbu; J.; Jaiswal, A. K. The human dioxin-inducible NAD(P)H:quinone oxidoreductase cDNA-encoded protein expressed in Cos-1 cells is identical to diaphorase-4. Eur. J. Biochem. 195:171-176; 1991.
58. Rothman, N.; Traver, R. D.; Smith, M. T.; Hayes, R. B.; Li, G-L.; Complemann, S.; Dosemeci, M.; Zhang, L.; Linet, M.; Wacnolder, S.; Yin, S-N.; Ross, D. Lack of NAD(P)H:quinone oxidoreductase activity (NQO1) is associated with an increased risk of benzene hemotoxicity. Proc. Am. Assoc. Cancer Res. 37:258; 1996.
59. Nebert, D. W. Invited editorial: Polymorphisms in drugmetabolizing enzymes: What is their clinical relevance and why do they exist? Am. J. Hum. Genet. 60:265-271; 1997.
60. Cummings, B. J.; Keane, T. J.; O'Sullivan, B.; Wong, C. S.; Catton, C. N. Mitomycin in anal canal carcinoma. Oncology 50(Suppl.l):63-69; 1993.
61. Hu, L-T.; Stamberg, J.; Pan, S-S. The NAD(P)H:quinone oxidoreductase locus in human colon carcinoma HCT 116 cells resistant to mitomycin C. Cancer Res. 56:5253-5259; 1996.
62. Begleiter, A.; Leith, M. Induction of DT-diaphorase by doxorubicin and combination therapy with mitomycin C in vitro. Biochem. Pharmacol. 50:1281-1286; 1995.
63. Gasdaska, P. Y.; Fisher, H.; Powis, G. An alternatively spliced form of NQO, (DT-diaphorase) messenger RNA lacking the putative quinone substrate binding site is present in normal and tumour tissues. Cancer Res. 55(12):2542-2547; 1995.
64. Siegel, D.; Beall, H.; Kasai, M.; Arai, H.; Gibson, N. W.; Ross, D. pH-dependent inactivation of DT-diaphorase by mitomycin C and porfiromycin. Mol. Pharmacol. 44:1128-1134; 1993.
65. Yao, K.; Xanthoudakis, S.; Curran, T.; O'Dwyer, P. J. Activation of AP-1 and of a nuclear redox factor, Red-1, in the response of HT29 colon cancer cells to hypoxia. Mol. Cell. Biol. 14(9):5997-6003; 1994.
66. Phillips, R. M.; de la Cruz, A.; Traver, R. D.; Gibson, N. W. Increased activity and expression of NAD(P)H:quinone acceptor oxidoreductase in confluent cell cultures and within multicellular spheroids. Cancer Res. 54:3766-3771; 1994.
67. Riley, R. J.; Workman, P. DT-diaphorase and cancer chemotherapy. Biochem. Pharmacol. 43:1657-1669; 1992.
68. Joseph, P.; Xu, Y.; Jaiswal, A. K. Non-enzymatic and enzymatic activation of mitomycin C: Identification of a unique cytosolic activity. Int. J. Cancer 65:263-271; 1996.
69. Bacham, H. M.; Inglis, R.; Chinje, E. C.; Stratford, I. J. Development and validation of a spectrophotometric assay for measuring the activity of NADHxytochrome b5 reductase in human tumour cells. Br. J. Cancer 74:1188-1193; 1996.
70. Chen, S.; Knox, R.; Wu, K.; Dong, P. S-K.; Zhou, D.; Bionchet, M. A.; Amzel, L. M. Molecular basis of the catalytic differences among DT-diaphorase of human, rat and mouse. Proc. Am. Assoc. Cancer Res. 38:560; 1997.
71. Knox, R. J.; Friedlos, F.; Jarman, M.; Davies, L. C.; Goddard. P.; Anlezark, G. M.; Melton, R. G.; Sherwood, R. F. Virtual cofactors for an Escherichia coli nitroreductase enzyme: Relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol. 49:1641-1647; 1995.